Retrieve available abstracts of 57 articles: HTML format
Single Articles
May 2025
ATERE AO, Mustapha FB, Mustapha MJ Logistics of the malaria vaccine roll-out in Nigeria.
Lancet. 2025;405:1815. PubMed
April 2025
MARQUES ETA, Burke DS Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine.
Lancet. 2025;405:1314-1315. PubMed
NDEMBI N, Karuna S, Cowden J, Cagigi A, et al Accelerating vaccine development in Africa: lessons from HIV research.
Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564. PubMed
March 2025
RICHARDSON JS, Anderson DM, Mendy J, Tindale LC, et al Chikungunya virus virus-like particle vaccine safety and immunogenicity in
adolescents and adults in the USA: a phase 3, randomised, double-blind,
placebo-controlled trial.
Lancet. 2025 Mar 27:S0140-6736(25)00345-9. doi: 10.1016/S0140-6736(25)00345. PubMedAbstract available
TINDALE LC, Richardson JS, Anderson DM, Mendy J, et al Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults
older than 65 years: a phase 3, randomised, double-blind, placebo-controlled
trial.
Lancet. 2025 Mar 27:S0140-6736(25)00372-1. doi: 10.1016/S0140-6736(25)00372. PubMedAbstract available
MENSAH AA, Whitaker H, Andrews NJ, Watson CH, et al Early impact of RSV vaccination in older adults in England.
Lancet. 2025 Mar 24:S0140-6736(25)00346-0. doi: 10.1016/S0140-6736(25)00346. PubMed
DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine
targeting serogroups A, C, W, Y, and X when co-administered with routine
childhood vaccines at ages 9 months and 15 months in Mali: a single-centre,
double-blind, randomised, c
Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046. PubMedAbstract available
ALVES L Brazil hopes for new vaccine to combat dengue.
Lancet. 2025;405:770. PubMed
February 2025
PRASAD A Sarah Blagden: designing vaccines for cancer prevention.
Lancet. 2025;405:613. PubMed
NEUPANE D, Jaiswal LS, Koirala S Nepal set to launch historic HPV vaccination programme.
Lancet. 2025;405:375. PubMed
January 2025
MUMFORD L, Hogg R, Taylor A, Lanyon P, et al Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation
rates in immunosuppressed populations during the omicron period: the MELODY
study.
Lancet. 2025;405:314-328. PubMedAbstract available
DATOO MS, Hill AVS, Beaumont E, Bradley J, et al The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Lancet. 2025;405:299-301. PubMed
AABY P, Bjorkman A, Schapira A, Benn CS, et al The R21/Matrix-M malaria vaccine: questions remain.
Lancet. 2025;405:299. PubMed
OBARO S, Mokuolu O, Michelow IC The R21/Matrix-M malaria vaccine: questions remain.
Lancet. 2025;405:299. PubMed
LI Y, Liu G The R21/Matrix-M malaria vaccine: questions remain.
Lancet. 2025;405:298-299. PubMed
IMPOUMA B, Adidja A, Mboussou F, Cabore J, et al Malaria vaccine introduction in Africa: progress and challenges.
Lancet. 2025 Jan 21:S0140-6736(24)02841-1. doi: 10.1016/S0140-6736(24)02841. PubMed
DZAU V, Hatchett R, Bishen S, Kaseya J, et al The time for regionalised vaccine manufacturing has arrived.
Lancet. 2025 Jan 14:S0140-6736(25)00050-9. doi: 10.1016/S0140-6736(25)00050. PubMed
December 2024
TONY YANG Y The perils of RFK Junior's anti-vaccine leadership for public health.
Lancet. 2024 Dec 18:S0140-6736(24)02603-5. doi: 10.1016/S0140-6736(24)02603. PubMed
November 2024
INO H, Takimoto Y, Nakazawa E Misinformation targeting replicon vaccine recipients: an urgent public health
ethical issue.
Lancet. 2024;404:1922-1923. PubMed
October 2024
PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated
hospitalisations and emergency department encounters among adults aged 60 years
and older in the USA, October, 2023, to March, 2024: a test-negative design
analysis.
Lancet. 2024;404:1547-1559. PubMedAbstract available
BRANDA F, Oh J, Acharya KP, Yon DK, et al Human vaccination for highly pathogenic avian influenza.
Lancet. 2024;404:1518-1519. PubMed
BRANCHE AR Real-world effectiveness studies of the benefit of RSV vaccines.
Lancet. 2024;404:1498-1500. PubMed
QADRI F, Khanam F, Zhang Y, Biswas PK, et al 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate
vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Lancet. 2024;404:1419-1429. PubMedAbstract available
AL-MAMUN F, Mamun MA, Roy N Long-term efficacy and public health implications of the Vi-tetanus toxoid
conjugate vaccine in Bangladeshi children.
Lancet. 2024;404:1378-1379. PubMed
September 2024
PHUYAL S, Acharya KP, Yon DK Antibody titres after vaccination: a missing key to rabies control.
Lancet. 2024;404:1192-1193. PubMed
SALEEM SM, Jan SS Operationalising the One Health approach for rabies elimination.
Lancet. 2024;404:1191-1192. PubMed
ADEPOJU P Vaccination under way as mpox cases continue to rise.
Lancet. 2024;404:1184. PubMed
MAZUR NI, Caballero MT, Nunes MC Severe respiratory syncytial virus infection in children: burden, management, and
emerging therapies.
Lancet. 2024;404:1143-1156. PubMedAbstract available
WALDMAN R, Steinglass R, Nieburg P An urgent case for measles vaccination in Gaza.
Lancet. 2024 Sep 20:S0140-6736(24)02076-2. doi: 10.1016/S0140-6736(24)02076. PubMed
PECENKA C, Sparrow E, Feikin DR, Srikantiah P, et al Respiratory syncytial virus vaccination and immunoprophylaxis: realising the
potential for protection of young children.
Lancet. 2024 Sep 6:S0140-6736(24)01699-4. doi: 10.1016/S0140-6736(24)01699. PubMedAbstract available
NTUMBA HCK, Mandja BM Mpox in eastern Democratic Republic of the Congo: challenges and prospects for
vaccination.
Lancet. 2024 Sep 2:S0140-6736(24)01806-3. doi: 10.1016/S0140-6736(24)01806. PubMed
August 2024
ZHONG L, Zhao Q, Zeng MS, Zhang X, et al Prophylactic vaccines against Epstein-Barr virus.
Lancet. 2024;404:845. PubMed
NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
Lancet. 2024;404:748. PubMed
OBARO S Efficacy of typhoid conjugate vaccine in Malawian children.
Lancet. 2024;404:747-748. PubMed
SCHIFFMAN M, de Sanjose S The rational design of cervical cancer prevention strategies.
Lancet. 2024;404:406-407. PubMed
July 2024
ADEPOJU P African mpox surges show lack of vaccine access.
Lancet. 2024;404:18. PubMed
June 2024
LI P, Meng Z, Zhou Z, Zhong Z, et al Therapeutic vaccines for Epstein-Barr virus: a way forward.
Lancet. 2024;403:2779-2780. PubMed
HO A, Galgut O, Faustini S, Peters N, et al Implications of suboptimal measles immunity in UK health-care workers.
Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011. PubMed
SAMARASEKERA U African vaccine manufacturing scheme to boost production.
Lancet. 2024;403:2579-2580. PubMed
ASHINZE P, Mafua N, Obafemi E Nigeria rolls out novel meningitis vaccine.
Lancet. 2024;403:2373. PubMed
May 2024
LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al Expanding antibiotic, vaccine, and diagnostics development and access to tackle
antimicrobial resistance.
Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878. PubMedAbstract available
ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al Cofinancing immunisation through national health insurance.
Lancet. 2024;403:1983-1984. PubMed
SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al Contribution of vaccination to improved survival and health: modelling 50 years
of the Expanded Programme on Immunization.
Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850. PubMedAbstract available
April 2024
COULBORN RM, Danet C, Alsalhani A Measles and rubella vaccine microneedle patch: new hope to reach the unreached
children.
Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749. PubMed
ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2,
double-blind, double-dummy, randomised, active-controlled, age de-escalation
trial.
Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532. PubMedAbstract available
ADEPOJU P Moderna stalls on African vaccine manufacturing plans.
Lancet. 2024;403:1617. PubMed
ASANTE KP, Mathanga DP, Milligan P, Akech S, et al Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when
implemented through national immunisation programmes: evaluation of
cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004. PubMedAbstract available
DAUBENBERGER CA, Silva JC First-generation malaria vaccine successfully implemented in three African
countries.
Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892. PubMed
March 2024
RAQIB R Bivalent conjugate vaccines for typhoid and paratyphoid fever.
Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461. PubMed
KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella
enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised,
active-controlled, double-blind trial.
Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249. PubMedAbstract available
BURKI T Pivotal tuberculosis vaccine trial begins.
Lancet. 2024;403:1125. PubMed
SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster
campaign.
Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316. PubMed
BURKI T The great cholera vaccine shortage.
Lancet. 2024;403:891-892. PubMed
PARHIZ H, Atochina-Vasserman EN, Weissman D mRNA-based therapeutics: looking beyond COVID-19 vaccines.
Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444. PubMedAbstract available
February 2024
OCHOGE M, Futa AC, Umesi A, Affleck L, et al Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young
children aged 1 to <5 years and lot-to-lot consistency of the immune response to
nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled
trial.
Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844. PubMedAbstract available
COOPER LV, Blake IM First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053. PubMed